Peritoneal adhesion is a complex fibrosis and inflammatory process, and it can be minimized by physical isolation by biomaterial membranes or treatment with cytostatic and/or anti-inflammatory drugs. However, the integration of physical isolation and pharmaceutical therapy in one platform faces many challenges. First, normal polymer antiadhesion membranes are hydrophobic and show low bioadhesion to the injured tissue, which decrease their efficacies. Second, the significantly different release behaviors of various drugs owing to their different hydrophilic/hydrophobic properties limit their synergistic effects. In this study, a highly bioadhesive polymer membrane formed by core–sheath nanofiber to integrate physical isolation and pharmaceutical treatment together for the synergistic prevention of peritoneal adhesion. 10-Hydroxycamptothecin (HCPT) and diclofenac sodium (DS) were loaded in the sheath and core of nanofiber, respectively. The membrane was then treated by ultraviolet-ozone (UVO) for improvement of hydrophilicity and bioadhesion. Owing to the core–sheath structure, the two drugs both performed a sustained release behavior for the cytostatic and anti-inflammatory effects. The in vivo study demonstrated that the UVO-treated and dual-drug-coloaded membrane possessed the best antiadhesion capacity, indicating its potential clinical application.

中文翻译：

---

高度生物粘附性的聚合物膜可连续释放抑制细胞生长和消炎作用的药物，以预防腹膜粘连

腹膜粘连是一个复杂的纤维化和炎症过程，可以通过生物材料膜的物理隔离或用抑制细胞生长和/或消炎的药物进行处理来最小化。然而，将物理隔离和药物治疗整合到一个平台中面临许多挑战。首先，普通的聚合物抗粘膜是疏水性的，对受损组织的生物粘附性很低，从而降低了它们的功效。其次，由于各种药物的不同的亲水/疏水特性，它们的释放行为明显不同，从而限制了它们的协同作用。在这项研究中，由芯-鞘纳米纤维形成的具有高生物粘附性的聚合物膜将物理隔离和药物处理结合在一起，可协同预防腹膜粘连。将10-羟基喜树碱（HCPT）和双氯芬酸钠（DS）分别装入纳米纤维的皮和芯中。然后将膜用紫外线臭氧（UVO）处理，以改善亲水性和生物粘附性。由于核心-鞘结构，这两种药物都具有抑制细胞生长和抗炎作用的持续释放行为。体内研究表明，经UVO处理且载有双药的膜具有最佳的抗粘附能力，表明其潜在的临床应用。两种药物均具有持续释放的抑制细胞生长和抗炎作用。体内研究表明，经UVO处理且载有双药的膜具有最佳的抗粘附能力，表明其潜在的临床应用。两种药物均具有持续释放的抑制细胞生长和抗炎作用。体内研究表明，经UVO处理且载有双药的膜具有最佳的抗粘附能力，表明其潜在的临床应用。